Marketing Weight-Loss Injections in the UK: What Pharmacies and Brands Can and Can’t Say

Here is the short version. Every injectable weight-loss medicine in the UK, including Wegovy, Mounjaro and Saxenda, plus the newly licensed oral GLP-1 tablets, is a prescription-only medicine, and it is illegal to advertise a prescription-only medicine to the public. In practice that means you cannot name the drugs, you cannot use phrases like “weight-loss injection”, “GLP-1” or “skinny jab”, you cannot show a picture of a pen, and you cannot get round any of it with an affiliate code or a clever landing page.

What you can promote is a weight-loss consultation and service, as long as you do not signal that the outcome is a prescription drug. This guide is the practical version of those rules, backed by the actual ASA, MHRA and GPhC enforcement that has reshaped this category through 2025 and 2026.

Why this is the riskiest category in healthcare marketing right now

Weight-loss medication is the single most heavily policed area in UK healthcare advertising. Demand is extraordinary, which makes the temptation to push the line enormous, which is exactly why the regulators are watching this category harder than any other.

The numbers tell the story. The MHRA took action against more than 25 businesses for promoting weight-loss prescription medicines to the public in 2025, the majority of them pharmacies. The ASA’s AI-based Active Ad Monitoring System flagged around 1,800 unique paid-for weight-loss ads as potentially promoting prescription medicines in a single December-to-January window. In September 2025 the ASA, MHRA and GPhC published an updated joint Enforcement Notice restating one blunt principle: no prescription-only medicine may be advertised to the public.

Enforcement has also escalated beyond warnings. It now runs to criminal prosecution, fitness-to-practise referrals for registered professionals, and public naming of non-compliant providers on an MHRA list. For a healthcare brand, being added to that list is a reputational problem that outlasts any single ad.

The core rule, in one sentence

All weight-loss injections are prescription-only medicines, and prescription-only medicines cannot be advertised to the public. This sits on two foundations that apply at the same time: the Human Medicines Regulations 2012, which make it unlawful, and rule 12.12 of the CAP Code, enforced by the ASA. The medicines in scope include Wegovy (semaglutide), Mounjaro (tirzepatide), Saxenda (liraglutide) and the newly licensed oral GLP-1 products. Every one of them is a POM.

What you cannot say or show, with the actual rulings

The ASA has now ruled on enough cases to remove the guesswork. The following all count as advertising a prescription-only medicine.

• The brand or drug name. Naming Mounjaro, Wegovy, Ozempic, semaglutide or tirzepatide is a breach. The ASA ruled against an online prescriber for naming the medicine (UK Meds Direct, February 2026), and against a product whose name embedded the drug, semaglutide inside “SemaPen” (SemaPen Ltd, July 2025).

• The drug class. Referring to “GLP-1” was ruled to be promotion of a POM (Juniper Technologies, July 2025). A recent joint warning extended this to “GLP-1 tablets”, “oral GLP-1s” and “the new weight-loss tablets” for the newly licensed oral products.

• Generic descriptors. “Weight-loss injection”, “weight-loss pen”, “obesity treatment jab” and “skinny jab” are all prohibited because every injectable weight-loss medicine is a POM (MHRA enforcement notice; “skinny jab” ruling, WLO Ltd, December 2025; “obesity treatment jab”, Express Healthcare, July 2025).

• Imagery of the medicine. Showing an injection pen, vial or packaging is enough to breach, even without naming anything (Hexpress Healthcare and Chequp Health, 2025).

• A consultation ad that leads to a POM. An ad offering a “weight-loss consultation” that links to a landing page showing a Mounjaro pen and inviting people to “choose your pen” is still advertising a POM (Chequp Health, July and December 2025).

• Price promotions and special offers on the medicines. The GPhC has been explicit that discounts and special price offers should not be used for prescription-only medicines.

• Affiliate links, referral codes and influencer posts. Posts that name the drugs, show pens or push a “journey” with a discount code are ads. The ASA ruled against the schemes behind Voy, Zava, MedExpress and UK Meds Direct, and made clear that brands are responsible for how their referral and affiliate schemes operate, even for posts they did not write themselves (February 2026).

• Supplements that imply a GLP-1 effect. Claiming a food or supplement works like a GLP-1 injection, or that it boosts GLP-1, makes it medicinal by presentation and breaches the rules (rulings against Arrae, Evolution Slimming and others, August 2025).

• Unlicensed or pipeline products. Promoting products that are not yet MHRA-authorised, including waiting lists for them, is prohibited. A medicine must hold a marketing authorisation before it can be marketed at all (rule 12.11).

The “consultation loophole” that is not one

You are allowed to advertise a consultation for weight loss. This is where most brands try to live, and where most of them still get caught. The ASA has closed the obvious workaround: an ad must not indicate, either through its own content or through a directly linked landing page, that the likely outcome is a prescription medicine.

So “book a weight-loss consultation” is fine in principle, but if it clicks through to a page selling named pens, or your only treatment on offer is plainly a POM, you are back in breach. Also be careful with claims that trivialise the clinical side, such as “no GP visit, just a two-minute online consultation”. Those have featured in rulings and they sit badly against the GPhC’s expectation that these medicines are only prescribed after a proper clinical assessment with independent verification that the medicine is appropriate.

What you actually can do: the compliant playbook

The constructive version is simpler than it looks. Promote the consultation, the programme and the credibility, not the drug.

• Market the service and the consultation, framed around clinical support, supervision, coaching and sustainable outcomes, rather than around a medicine.

• Educate. Content on obesity, metabolic health, the role of proper assessment and lifestyle change builds authority and trust without ever naming a POM.

• Promote what you are allowed to promote: programmes, nutrition and lifestyle support, and any non-POM products within the terms of their authorisation.

• Lead with credibility. In a category crowded with cut-corner operators, visible clinicians, GPhC registration, safety and aftercare are your strongest differentiators.

• Use patient stories about the experience, the support and the change in their life, not about the medicine or how much weight a named drug produced.

• Control your creators. Put compliance rules into affiliate, referral and influencer contracts so participants cannot name POMs, show pens or use banned terms, and monitor what they actually post.

Extra rules if you are a pharmacy

Pharmacies are the primary target of the joint enforcement notice, so the bar is higher. The GPhC inspects against its Guidance for registered pharmacies providing pharmacy services at a distance, including on the internet, and looks for evidence that you follow it. Prescribing has to rest on a genuine clinical assessment, with the prescriber independently verifying that the medicine is clinically appropriate, not on a thin online questionnaire. Special price offers on the medicines are out. And individual pharmacists and prescribers can face fitness-to-practise action in their own name, separately from anything that happens to the business.

Social, affiliates and influencers: the newest enforcement frontier

This is the part that catches brands who think their website is clean. Organic posts, stories, hashtags, customer referral posts and influencer content all count as advertising. The ASA has stated plainly that affiliate marketing does not get round the rules, and that both the brand and the individual are responsible. If your referral scheme rewards customers for posts that name a drug or show a pen, the design of that scheme is your liability.

There is a further wrinkle worth knowing. ASA consumer research published in April 2026 found that people often read weight-loss service ads as promoting prescription medicines even when no drug is named, partly because many do not realise these are prescription-only in the first place. That means tone and context matter, not just the literal words, so the safest content keeps the focus firmly on the service and the consultation.

A compliant content plan that still drives bookings

Pulling it together, a weight-loss service can grow hard and stay compliant with a plan like this.

• Lead with education, clinical credibility and programme content, so you never depend on the medicines you are not allowed to name.

• Use goal-led and health-led hooks, for example energy, confidence and lasting change, that route to a consultation rather than to a named drug or a pen.

• Feature real testimonials about support and experience, screened so they do not name medicines or quote drug-specific results.

• Run strict creator and affiliate compliance, with contract terms and active monitoring.

• Use a consultation call to action that never promises a prescription outcome.

This is precisely the kind of system a specialist healthcare social and paid media partner builds and polices, so the brand gets the growth without becoming the next published ruling.

Quick compliance checklist to action today

• Remove all drug names, “GLP-1”, “weight-loss injection”, “jab”, “pen” and “skinny jab” from public content.

• Remove injection pen, vial and packaging imagery.

• Check every consultation ad, and its landing page, does not lead to or imply a POM.

• Kill price promotions and special offers on the medicines.

• Audit affiliate, referral and influencer content and tighten the contracts behind them.

• Remove supplement claims that compare to GLP-1s or claim to boost GLP-1.

• Remove any promotion of unlicensed or pipeline products and waiting lists.

• If you are a pharmacy, check your distance-selling compliance and remove claims that trivialise clinical assessment.

Frequently asked questions

Can I say “weight-loss injection” if I do not name the brand?

No. The ASA treats generic terms such as “weight-loss injection”, “weight-loss pen” and “obesity treatment jab” as advertising a prescription-only medicine, because all injectable weight-loss medicines are prescription-only.

Can I advertise a weight-loss consultation?

Yes, but the ad and any linked landing page must not indicate that the likely outcome is a prescription medicine. Promote the consultation and the service, not the drug.

Are affiliate links and influencer posts really covered?

Yes. The ASA has ruled that affiliate and referral posts naming weight-loss prescription medicines are ads, and that brands are responsible for how their schemes operate, even for posts they did not write.

Can my supplement say it works like Ozempic or boosts GLP-1?

No. Comparing a food or supplement to a GLP-1 medicine, or claiming it boosts GLP-1, makes it medicinal by presentation and breaches the rules.

Is this a new ban?

No. Advertising prescription-only medicines to the public has long been unlawful. What changed in 2025 and 2026 is far stronger, coordinated enforcement by the ASA, MHRA and GPhC, including AI monitoring and public naming.

What are the penalties?

They range from required ad removal and public naming on an MHRA list, through to criminal prosecution, and, for registered professionals, fitness-to-practise referrals.

Grow your weight-loss service without earning a ruling

Otta builds compliant, high-performing social and paid media for healthcare and pharmacy brands, including weight-management services, so the rules are designed into your content and your campaigns from the start. If you want growth in this category without ending up on a regulator’s list, get in touch and we will show you what compliant, commercial marketing looks like here.

This article is general guidance, not legal advice. Advertising and medicines rules change quickly in this area, so always check the current ASA CAP Code, the joint Enforcement Notice and MHRA guidance before publishing.

Sources and further reading

ASA / CAP, weight control: prescription-only medicines

ASA / MHRA / GPhC joint Enforcement Notice on weight-management POMs

GOV.UK, MHRA reaffirms prescription weight-loss medicine advertising rules